Management Inattention Is Root Cause Of Many QS Compliance Problems
This article was originally published in The Silver Sheet
Executive Summary
ANNUAL QUALITY SYSTEM WARNING LETTER ANALYSIS finds the number of letters rising to previous norms, with 108 issued in 2004. CDRH Office of Compliance Director Ulatowski has sharp words for device company execs who are remiss in their duty to ensure manufacturing quality, saying it is often "extremely apparent they don’t understand what their obligations are" under the Quality System reg. CAPA, management responsibility and complaint handling are the top three citation areas
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.